Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:APOP OTCMKTS:MDIT NASDAQ:OBLN NASDAQ:PSTV On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeAPOPCellect Biotechnology$11.51$6.64▼$35.52$12.87M1.87479,845 shs17,400 shsMDITCytoCore$0.01$0.00$0.01▼$0.01N/A101.87639 shs10 shsOBLNObalon Therapeutics$6.61+4.6%$4.22$0.66▼$10.77$66.25M-1.237.68 million shs328,834 shsPSTVPlus Therapeutics$0.43+3.5%$0.51$0.16▼$2.31$41.35M0.665.42 million shs8.25 million shs7 Stocks That Could Be Bigger Than Tesla, Nvidia, and GoogleLooking for the next FAANG stock before everyone has heard about it? Enter your email address to see which stocks MarketBeat analysts think might become the next trillion dollar tech company.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceAPOPCellect Biotechnology0.00%0.00%0.00%0.00%0.00%MDITCytoCore0.00%0.00%+4,900.00%+4,900.00%+4,900.00%OBLNObalon Therapeutics+4.55%-21.39%-27.61%+146.88%+3,820.60%PSTVPlus Therapeutics+3.48%-8.26%-17.59%+122.22%-73.39%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeAPOPCellect Biotechnology$11.51$6.64▼$35.52$12.87M1.87479,845 shs17,400 shsMDITCytoCore$0.01$0.00$0.01▼$0.01N/A101.87639 shs10 shsOBLNObalon Therapeutics$6.61+4.6%$4.22$0.66▼$10.77$66.25M-1.237.68 million shs328,834 shsPSTVPlus Therapeutics$0.43+3.5%$0.51$0.16▼$2.31$41.35M0.665.42 million shs8.25 million shs7 Stocks That Could Be Bigger Than Tesla, Nvidia, and GoogleLooking for the next FAANG stock before everyone has heard about it? Enter your email address to see which stocks MarketBeat analysts think might become the next trillion dollar tech company.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceAPOPCellect Biotechnology0.00%0.00%0.00%0.00%0.00%MDITCytoCore0.00%0.00%+4,900.00%+4,900.00%+4,900.00%OBLNObalon Therapeutics+4.55%-21.39%-27.61%+146.88%+3,820.60%PSTVPlus Therapeutics+3.48%-8.26%-17.59%+122.22%-73.39%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceAPOPCellect Biotechnology 0.00N/AN/AN/AMDITCytoCore 0.00N/AN/AN/AOBLNObalon Therapeutics 0.00N/AN/AN/APSTVPlus Therapeutics 3.20Buy$7.881,726.72% UpsideCurrent Analyst Ratings BreakdownLatest PSTV, OBLN, MDIT, and APOP Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails9/18/2025PSTVPlus TherapeuticsD. Boral CapitalSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$5.009/3/2025PSTVPlus TherapeuticsD Boral CapitalSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeHold ➝ Strong-Buy9/3/2025PSTVPlus TherapeuticsD. Boral CapitalSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeHold ➝ Buy$5.008/18/2025PSTVPlus TherapeuticsMaxim GroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetBuy$4.00 ➝ $3.006/27/2025PSTVPlus TherapeuticsHC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetBuy$5.50 ➝ $3.006/25/2025PSTVPlus TherapeuticsD. Boral CapitalSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingHold$9.00(Data available from 9/19/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookAPOPCellect BiotechnologyN/AN/AN/AN/A$4.77 per shareN/AMDITCytoCoreN/AN/AN/AN/AN/AN/AOBLNObalon Therapeutics$1.59M41.66N/AN/A$0.60 per share11.02PSTVPlus TherapeuticsN/AN/AN/AN/A($1.52) per shareN/ACompare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateAPOPCellect Biotechnology-$5.62MN/A0.00N/AN/AN/AN/AN/AN/AMDITCytoCoreN/AN/A0.00∞N/AN/AN/AN/AN/AOBLNObalon Therapeutics-$12.33MN/AN/A∞N/A-776.76%-161.38%-83.58%N/APSTVPlus Therapeutics-$12.98M-$2.24N/AN/AN/A-357.85%N/A-117.72%11/13/2025 (Estimated)Latest PSTV, OBLN, MDIT, and APOP EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails8/14/2025Q2 2025PSTVPlus Therapeutics-$0.09-$0.01+$0.08-$0.01$1.08 million$1.39 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthAPOPCellect BiotechnologyN/AN/AN/AN/AN/AMDITCytoCoreN/AN/AN/AN/AN/AOBLNObalon TherapeuticsN/AN/AN/AN/AN/APSTVPlus TherapeuticsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioAPOPCellect BiotechnologyN/A3.013.01MDITCytoCoreN/AN/AN/AOBLNObalon TherapeuticsN/A1.861.86PSTVPlus TherapeuticsN/A1.261.26Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipAPOPCellect Biotechnology4.84%MDITCytoCoreN/AOBLNObalon Therapeutics18.64%PSTVPlus Therapeutics3.28%Insider OwnershipCompanyInsider OwnershipAPOPCellect BiotechnologyN/AMDITCytoCore85.40%OBLNObalon Therapeutics8.10%PSTVPlus Therapeutics0.79%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableAPOPCellect Biotechnology2,020977,000N/ANot OptionableMDITCytoCore71N/AN/ANot OptionableOBLNObalon Therapeutics210.02 millionN/ANot OptionablePSTVPlus Therapeutics2099.27 million98.48 millionNot OptionablePSTV, OBLN, MDIT, and APOP HeadlinesRecent News About These CompaniesPlus Therapeutics' (PSTV) Buy Rating Reiterated at D. Boral CapitalSeptember 19 at 2:25 AM | americanbankingnews.comPlus Therapeutics Announces Successful Accreditation and Certification for Its CNSide® Diagnostics Clinical LaboratorySeptember 18 at 11:16 AM | finance.yahoo.comCNSide Diagnostics Receives CMS Accreditation for CSF Assay Platform, Advancing Market Access for CNS Cancer TestingSeptember 18 at 7:51 AM | quiverquant.comQPlus Therapeutics Announces Successful Accreditation and Certification for Its CNSide® Diagnostics Clinical LaboratorySeptember 18 at 7:30 AM | globenewswire.comBrokerages Set Plus Therapeutics, Inc. (NASDAQ:PSTV) PT at $7.88September 15, 2025 | americanbankingnews.comHead to Head Analysis: Plus Therapeutics (NASDAQ:PSTV) and Gain Therapeutics (NASDAQ:GANX)September 8, 2025 | americanbankingnews.comPlus Therapeutics upgraded to Buy from Hold at D. Boral CapitalSeptember 3, 2025 | msn.comD. Boral Capital Upgrades Plus Therapeutics (PSTV)September 3, 2025 | msn.comPlus Therapeutics to Participate in Fireside Chat at the H.C. Wainwright 27th Annual Global Investment ConferenceSeptember 3, 2025 | finance.yahoo.comPlus Therapeutics to Participate in Fireside Chat at the H.C. Wainwright 27th Annual Global Investment ConferenceSeptember 2, 2025 | globenewswire.comPlus Therapeutics Secures Nasdaq Compliance ExtensionAugust 26, 2025 | msn.comPlus Therapeutics, Inc. Confirms Compliance with Nasdaq Listing Rules Ahead of Grace Period ExpirationAugust 26, 2025 | quiverquant.comQPlus Therapeutics Regains Compliance with Applicable Nasdaq Listing CriteriaAugust 26, 2025 | globenewswire.comPlus Therapeutics (NASDAQ:PSTV) Director Acquires $53,900.00 in StockAugust 26, 2025 | insidertrades.comPlus Therapeutics price target lowered to $3 from $4 at MaximAugust 19, 2025 | msn.comPlus Therapeutics presents results from ReSPECT-LM Phase 1 trialAugust 19, 2025 | msn.comPlus Therapeutics Presents Positive ReSPECT-LM Clinical Trial Results of REYOBIQ™ in Leptomeningeal MetastasesAugust 18, 2025 | globenewswire.comPlus Therapeutics Reports Strong Q2 2025 ResultsAugust 16, 2025 | msn.comPlus Therapeutics Reports $3M in Stock EquityAugust 16, 2025 | baystreet.caPlus Therapeutics Reports $3M in Stock EquityAugust 16, 2025 | baystreet.caNew MarketBeat Followers Over TimeMedia Sentiment Over TimePSTV, OBLN, MDIT, and APOP Company DescriptionsCellect Biotechnology NASDAQ:APOPCellect Biotechnology Ltd. engages in the provision of regenerative medicine. Its activities include development of regenerative medicine through the development of products facilitating immune stem cell selection. The company also develops innovative technology, which allows the default stem cells by dramatically reducing of complications existing in conventional selection methods. The company was founded by Kasbian Nuriel Chirich, Shai Yarkoni, and Nadir Askenasy on August 4, 1986 and is headquartered in Kfar Saba, Israel.CytoCore OTCMKTS:MDIT$0.0050 0.00 (0.00%) As of 09/16/2025Medite Cancer Diagnostics, Inc. operates as a medical technology company. It develops, manufactures, and markets molecular biomarkers, medical devices, and consumables for the detection, risk assessment, and diagnosis of cancerous and precancerous conditions and related diseases. The company offers USE 33, an ultrasonic decalcification instrument that automatically runs the process under controlled temperatures; TPC 15 Duo and Trio, a tissue processing instrument; TES 99 and TES Valida cooling units; and M530, A550, M380 microtomes for tissue sectioning. It also provides M630, a freezing microtome; TST44, a robotic multi-staining system; COT 20, a linear staining system; and RCM 9000, ACS 720, and TWISTER robotic coverslippers. In addition, the company develops SoftKit device for the self-collection of a sample that can be evaluated to provide an assessment of the health of the entire female genital tract. It sells its products through direct sales and distributors in the United States, China, Europe, and North Africa. The company serves histology and cytology laboratories associated with hospitals or research institutions, and independent laboratories. Medite Cancer Diagnostics, Inc. is based in Orlando, Florida.Obalon Therapeutics NASDAQ:OBLNObalon Therapeutics, Inc., a vertically integrated medical device company, focuses on developing and commercializing medical devices to treat people with obesity. The company offers the Obalon Balloon System designed to provide weight loss in patients with obesity. Its Obalon Balloon System comprises of a swallowable capsule that contains an inflatable balloon attached to a microcatheter; the Obalon Navigation System console, which is a combination of hardware and software used to track and display the location of the balloon during placement; the Obalon Touch Inflation Dispenser, which is a semi-automated, hand-held inflation device used to inflate the balloon once it is placed; and a disposable canister filled with mixture of gas. Obalon Therapeutics, Inc. was incorporated in 2008 and is headquartered in Carlsbad, California.Plus Therapeutics NASDAQ:PSTV$0.43 +0.01 (+3.48%) Closing price 09/18/2025 04:00 PM EasternExtended Trading$0.44 +0.00 (+1.14%) As of 08:57 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Plus Therapeutics, Inc., a clinical-stage pharmaceutical company, focuses on the development, manufacture, and commercialization of treatments for patients with cancer. Its lead radiotherapeutic drug candidate is rhenium (186Re) obisbemeda, a patented radiotherapy that targets central nervous system cancers and other cancers, including recurrent glioblastoma, leptomeningeal metastases, and pediatric brain cancers. The company also develops Rhenium-188 NanoLiposome Biodegradable Alginate Microsphere that is designed to treat various solid organ cancers comprising primary and secondary liver cancers by intra-arterial injection. It has license agreements with NanoTx, Corp. and The University of Texas Health Science Center at San Antonio. The company was formerly known as Cytori Therapeutics, Inc. and changed its name to Plus Therapeutics, Inc. in July 2019. Plus Therapeutics, Inc. was founded in 1996 and is headquartered in Austin, Texas. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas The Fed Cut Rates: What Now for the S&P 500 and Equity Markets? Joby's Stock Is Quiet, But Its Commercial Engine Is In Overdrive Eli Lilly’s Oral GLP-1 Breakthrough Could Change Everything Bloom Energy Booms on AI Power Demand and Analyst Upgrades Can Apple’s iPhone 17 and AI Push Its Stock to New Highs? Why Seagate Is Wall Street's New Favorite AI Infrastructure Play New Catalysts Build Positive Pressure on Intel Stock Oracle to Hit $1 Trillion Valuation in 2025: Here’s Why Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
